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To the Editor:
Diffuse large B-cell lymphoma (DLBCL) is a hetero-
geneous disease. Patients carrying the double expression of
MYC and BCL2 (double expressor, DE) with or without
concomitant translocations of MYC and BCL2, and/or
BCL6 genes have a dismal prognosis. In patients affected
by DE DLBCL without translocations, the 5-year overall
survival (OS) is ~40% with R-CHOP. In high grade B-cell
lymphomas [i.e., double hit (DH) or triple hit (TH) lym-
phomas], the median OS is ~12 months [1–6]. Therefore, no
standard therapy for these disease entities exists, and their
optimal treatment represents an urgent unmet clinical need.
At our Institution, the DA-EPOCH-R has been adopted
for all DE DLBCL patients since 2013. The present study
compared the outcome of patients treated in a similar period
at three different Italian institutions with DA-EPOCH-R and
R-CHOP. We estimated the propensity score (PS) as a
balancing score to account for the biases consistent with a
non-random treatment assignment. The treatment effect in
the multivariable Cox models was estimated using an
inverse-probability-of-treatment-weight (IPTW) based on
PS [7].
Diagnosis was performed according to the WHO clas-
siﬁcation and was reviewed by two expert hematopatholo-
gists [patients with primary mediastinal and human
immunodeﬁciency virus-associated lymphomas or central
nervous system (CNS) disease were excluded]. Immuno-
histochemistry analysis and FISH were performed in all
patients and are detailed in Supplementary Appendix. The
cut-off levels for positivity for MYC and BCL2 were ≥40%
and ≥50%, respectively [8]. In this analysis, we included
stages II–IV or stage I disease with an International Prog-
nostic Index (IPI) score ≥ 1 or bulky disease. The Ethical
Committees of participating centers approved the study
(INT55/17). Written informed consent was obtained from
all patients.
The DA-EPOCH-R regimen was administered as pre-
viously described every 21 days for 6 cycles and dose-
adjustment was based on blood counts between cycles [9].
R-CHOP was administered every 21 days. CNS prophylaxis
with lumbar puncture or intravenous methotrexate was
administered according to institutional guidelines. Disease
assessment during the study was described in Supplemen-
tary Appendix.
These authors contributed equally: A. Dodero, A. Guidetti
* A. Guidetti
anna.guidetti@istitutotumori.mi.it
anna.guidetti@unimi.it
1 Department of Hematology, Fondazione IRCCS Istituto Nazionale
dei Tumori, Milano, Italy
2 Department of Oncology and Hemato-Oncology, University of
Milano, Milano, Italy
3 Department of Hematology, Azienda Ospedaliera Spedali Civili di
Brescia, Brescia, Italy
4 Department of Clinical Epidemiology and Trial Organization,
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
5 Department of Hematology, Azienda Ospedaliero Universitaria
Citta’ della Salute e della Scienza di Torino, Torino, Italy
6 Department of Pathology, Fondazione IRCCS Istituto Nazionale
dei Tumori, Milano, Italy
7 Department of Pathology, Azienda Ospedaliera Spedali Civili di
Brescia, Brescia, Italy
Supplementary information The online version of this article (https://
doi.org/10.1038/s41375-018-0320-9) contains supplementary
material, which is available to authorized users.
12
34
56
78
90
()
;,:
12
34
56
78
90
();
,:
The primary objective of the study was to compare the 2-
year PFS and OS in the DA-EPOCH-R and R-CHOP
cohorts. Secondary objectives included comparisons of
survival according to different prognostic factors (age,
stage, IPI, cell of origin and cytogenetic characterization).
Statistical Methods are summarized in Supplementary
Appendix.
A total of 114 consecutive patients were identiﬁed for the
study. Table 1 summarizes the main clinical and biological
characteristics of the patients. Fifty-one patients received
DA-EPOCH-R between October 2013 and October 2017
while 63 patients were treated with R-CHOP between
October 2009 and October 2017. Cohorts were well
balanced across all covariates included in the PS model after
IPTW adjustment as indicated by the standardized mean
difference (SMD) values calculated after weighting (<0.1).
The overall response rates were 80% [CR, n= 37 (73%);
PR, n= 4], and 76% [CR, n= 44 (71%); PR, n= 4] fol-
lowing DA-EPOCH-R and R-CHOP, respectively.
Patients in the R-CHOP group received less CNS pro-
phylaxis compared to those treated with DA-EPOCH-R
(30% vs 96%). In particular, since 2016 patients in
the DA-EPOCH-R group [23 of 51 (45%)] received four
lumbar punctures with methotrexate, cytarabine, and
dexamethasone followed by intravenous Methotrexate
(3.5 g/ms, for 2 courses) whereas all other patients received
triple intrathecal prophylaxis only. CNS relapses following
DA-EPOCH-R and R-CHOP were observed in one and
three patients, respectively. Consolidative radiotherapy was
administered in 21% and 35% of the patients in the DA-
EPOCH-R and R-CHOP cohorts, respectively. Death
occurred in 6 (12%) patients receiving DA-EPOCH-R [PD
(n= 4), pneumonia (n= 1), suicide (n= 1)], and in 22
(35%) R-CHOP patients [PD (n= 20), toxicity (n= 2)],
respectively.
DA-EPOCH-R dose escalation was feasible in most
patients aged ≤65 years with 73% of the patients being
escalated to the 3rd dose level or above (Supplementary
Figure 1). In contrast, the majority of the elderly patients
(≥65 years) received therapy at level 1 (11 out of 14, 78%)
due to comorbidities and toxicities. Supplementary Table 1
lists the primary toxicities observed during DA-EPOCH-R.
Therapy discontinuation due to adverse events occurred in
two patients per arm [DA-EPOCH-R: pneumonia (Grade 5)
and infection (alive in CR); R-CHOP: toxicity (Grade 5,
n= 2)].
Median follow-ups were 20 and 49 months in the DA-
EPOCH-R and R-CHOP group, respectively. The 2-year
PFS and OS, before IPTW adjustment, were 62% (95% CI:
45–84%) and 85% (95% CI: 74–98%) following DA-
EPOCH-R and 54% (95% CI: 43–69%) and 70% (95% CI:
60–83%) following R-CHOP, respectively. After weighting
no signiﬁcant statistical differences in the 2-year PFS (57%
vs 51%, p= 0.198) or OS (90% vs 67%, p= 0.07) were
observed following DA-EPOCH-R or R-CHOP, respec-
tively (Fig. 1a, b).
We then used an IPTW based on PS to estimate the
potential impact of the two regimens on age (≤65 vs >65),
disease stage (limited vs advanced), IPI [low risk (IPI 1–2)
vs high risk (IPI 3–5)], non-Germinal Center B-cell like
subgroup. In this analysis, age emerged as a clinically
relevant variable. In fact, patients aged <65 years treated
Table 1 Clinical and biological characteristics
Variable ALL DA-EPOCH-R R-CHOP SMD before/after
N= 114 N= 51 N= 63
Age
Median 62 years 58 years 65 years 0.296/<0.001
Range 29–81 29–79 36–81
Age > 65 years 43 (38%) 14 (27%) 29 (46%)
Sex
Male 70 (62%) 32 (63%) 38 (60%) 0.049/0.018
Female 44 (38%) 19 (37%) 25 (40%)
Histology
DLBCL 106 (93%) 47(92%) 59 (94%)
Transformed 8 (7%) 4 (8%) 4 (6%) —
Stage
I–II 28 (25%) 8 (16%) 20 (32%) 0.850/0.079
III–IV 86 (75%) 43 (84%) 43 (68%)
IPI
1–2 62 (54%) 24 (47%) 38 (60%) 0.332/0.101
3–5 52 (46%) 27 (53%) 25 (40%)
BM involvement
Yes 22 (19%) 16 (32%) 6 (10%) 0.552/0.421
No 92 (81%) 35 (68%) 57 (90%)
Extranodal involvementa
Yes 69 (60%) 46 (90%) 23 (36%) —
No 45 (40%) 5 (10%) 40 (64%)
CNS involvement
Leptomeningeal 3 (3%) 2 (4%) 1 (1%) —
Cytogenetic abnormalities
DE-only 58 (51%) 18 (35%) 40 (63%) 0.749/0.119
DE with SH 29 (25%) 16 (31%) 13 (21%)
DE with DH/TH 10 (9%) 8 (16%) 2 (3%)
DE with atypical DH 15 (13%) 9 (18%) 6 (10%)
Missing 2 (2%) 0 (0%) 2 (3%)
FISH rearrangements
MYC R 7 (6%) 5 (10%) —
BCL2 R 8 (7%) 5 (10%) 2 (3%)
BCL6 R 14 (12%) 6 (12%) 3 (5%)
MYC R/BCL2 R 5 (4%) 4 (7%) 8 (13%)
MYC R/BCL6 R 2 (2%) 2 (4%) 1 (2%)
MYC R/BCL2 R/BCL6 R 3 (3%) 2 (4%) 0 (0%)
Cell of origin (Hans) 0.334/0.049
GCB 42 (37%) 22 (43%) 20 (31%)
Non GCB 57 (50%) 25 (49%) 32 (51%)
Not evaluable 15 (13%) 4 (8%) 11 (18%)
SMD Standardized mean difference calculated before and after
weighting, DLBCL diffuse large B-cell lymphomas, BM bone marrow,
FISH ﬂuorescence in situ hybridization, DE double expressor, SH
single-hit, DH double hit, TH triple hit, R rearrangements, GCB
germinal center B-cell lymphomas
aAt least one extranodal involvement
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with DA-EPOCH-R exhibited a better PFS [82% (95% CI:
66–100%) vs 43% (95% CI: 26–73%), p= 0.020] and a
better OS [90% (95% CI: 74–100%) vs 62% (95% CI: 43–
88%), p= 0.042] compared to those receiving R-CHOP
(Fig. 1c, d). We did not observe any signiﬁcant advantage
for any other subgroup.
Fig. 1 Weighted Kaplan–Meier curves of progression-free survival (a)
and overall survival (b) in all patients according to treatment (DA-
EPOCH-R or R-CHOP); Weighted Kaplan–Meier curves of
progression-free survival (c) and overall survival (d) according to
treatment in patients younger than 65 years. Weighted Kaplan–Meier
estimates of progression-free survival according to biology (DE
patients with cytogenetic alteration such as SH, DH/TH, or atypical
DH deﬁned as “other” vs patients without any abnormalities deﬁned as
“DE-only”) and treatment (e)
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Analyses with IPTW adjustment were also performed on
the entire cohort according to treatment (DA-EPOCH-R vs
R-CHOP) and absence or presence of genetic lesions (DE-
only including patients lacking cytogenetic alterations, vs
“other” including single-hit, DH/TH or atypical DH patients
[10]). The subgroup of patients with any type of cytogenetic
abnormality treated with R-CHOP, had a worse 2-year PFS
compared to the other subgroups (41% vs 59%, p < 0.001)
(Fig. 1e).
Survival analysis of the entire study population revealed
similar OS and PFS for R-CHOP and DA-EPOCH-R
patients. In contrast, patients younger than 65 years
achieved a 2-year PFS of 82%, which was signiﬁcantly
better than the PFS observed with R-CHOP. Most of the
patients older than 65 years were treated with the ﬁrst dose
level compared to the group of younger patients who gen-
erally received level 3 or above (73% of cases) (Supple-
mentary Figure 1). This suggests that the efﬁcacy of the
treatment in the younger population might be ascribed to the
higher cumulative dose of chemotherapy received and not
only to the continuous infusion of the drugs.
A possible counfounding factor in this study relates to
CNS prophylaxis which varied over time. Biomarkers
inﬂuencing CNS relapse risk, independently from clinical
risk model (CNS-IPI), are in fact a recent acquisition.
However, the observed rate of CNS relapse is in line with
previous publications describing a risk of 13% and 9.7% at
2 years in patients affected by DH/TH and DE lymphomas,
respectively [11, 12].
In this retrospective study, possible biases between R-
CHOP and DA-EPOCH-R cohorts were balanced using
stabilized IPTW based on the PS in all survival analyses.
Our results indicate the potential role of DA-EPOCH-R in
the treatment of DE DLBCL patients mainly because of
three relevant observations: (1) treatment with DA-EPOCH-
R compared to R-CHOP was associated with a signiﬁcant
improvement of PFS and OS in patients younger than 65
years; (2) all patients with genetic abnormalities (single
translocations, atypical DH, and DH/TH) had better PFS
with DA-EPOCH-R; and (3) intensiﬁcation with DA-
EPOCH-R was feasible and safe in young patients.
It is clear that the optimal chemo-immunotherapy for
patients affected by DE DLBCL with or without gene
rearrangements is still a matter of debate. However, the
results observed with R-CHOP are considered unsatisfac-
tory, and most published studies using more intensive
regimens were retrospective and limited to the DH/TH
subgroup [13, 14]. To our knowledge, this is the ﬁrst report
analyzing the survival of a consecutive cohort of genetically
characterized DE patients treated with DA-EPOCH-R. In
addition to DH/TH lymphomas, ~30–50% of patients in
both cohorts exhibited single translocations or were atypical
DH. We observed that DE patients carrying any genetic
abnormality had a poor PFS when treated with R-CHOP
while they experienced a signiﬁcantly better outcome with
DA-EPOCH-R. Separate survival analyses according to
single cytogenetic alteration or combining age and cytoge-
netic alterations were not possible because of the limited
number of patients in each subgroup.
It is true that the median follow-up for DA-EPOCH-R
(20 months) cohort is shorter than R-CHOP (49 months),
but recent studies showed that PFS at 24 months is a
valuable surrogate end-point for OS in DLBCL patients
[15]. The 2-year PFS following DA-EPOCH-R in younger
patients is promising, but a prospective trial is required to
conﬁrm these ﬁndings.
In conclusion, the DA-EPOCH-R regimen is feasible in
patients up to 79 years of age, but the advantage of using an
intensive regimen is likely related to the dose escalation.
The results of the present study suggest that intensive
chemotherapy, such as DA-EPOCH-R, should be con-
sidered for patients with DE DLBCL aged less than 65
years.
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